ArticleJournal of translational medicine2026
Clinicopathological observation and initial exploration of characteristic biomarkers in breast apocrine carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study seeks to characterize the clinicopathological features of a cohort of breast apocrine carcinomas (AC) in the Chinese population, investigate their biological properties through immunohistochemistry and proteomics, and conduct a preliminary exploration of their biologically relevant molecules.
methodsSpecimens from 12 female patients (median age 52 years) with AC of the breast were obtained from the Department of Pathology of Shandong University of Traditional Chinese Medicine Affiliated Hospital from 2019 to 2024. Clinical pathological features were observed, and relevant immunohistochemical staining and KEGG pathway enrichment analysis were performed. Additionally, three cases each of triple-negative apocrine carcinoma (TNAC) and luminal androgen receptor triple-negative breast cancer (LAR-TNBC) were included for comparative analysis. Proteomic profiling and assessment of TRPS1 gene amplification were performed to elucidate the differences between these entities.
resultsIn 75% of patients (9/12), the tumours were located in the upper outer quadrant; 50% (6/12) exhibited invasive apocrine carcinoma (IAC) with apocrine-type ductal carcinoma in situ (ADCIS). All cases exhibited an apocrine morphology and were AR/GCDFP-15 positive and ER/PR-negative. CD10 was expressed in a patchy pattern in the marginal zone of the breast in IAC and was highly expressed in ADCIS but not expressed in apocrine metaplasia. The linear development pattern of breast AC (6 cases) was significantly associated with Her-2 positivity (66.7% vs. 33.3%). Hypoxia-inducible factor-1α(HIF-1α) expression was significantly higher in IAC than in ADCIS (p < 0.01) and was associated with invasion. IL-10 was continuously highly expressed in the tumour microenvironment. KEGG analysis revealed AR-Cyclin D1 pathway enrichment; the proteomic analysis revealed significant differences between the TNAC and LAR-TNBC groups (more than 200 differentially expressed proteins (DEPs)).TRPS1 amplification was significantly greater in the LAR-TNBC group (100%, 3/3) than in the AC group. The median follow-up was 6–39 months, with no recurrence or metastasis (100% disease-free survival).
conclusionsAC exhibits unique AR-driven characteristics and an apocrine morphological lineage. CD10, Cyclin D1, and HIF-1α are potential biologically relevant markers. TNAC significantly differs from LAR-TNBC in terms of its proteomic and TRPS1 amplification characteristics, supporting its classification as an independent disease type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.